Figure 1.
Risankizumab mean plasma concentration‐time profile following single subcutaneous (SC) doses in panels A, B, and C or intravenous (IV) doses in panel D in healthy subjects.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.